ASH 2014: Highlights in Hodgkin Lymphoma

ASH 2014: Highlights in Hodgkin Lymphoma published on December 16, 2014
Massimo Federico, MD discusses Long-Term Follow-up Analysis of HD2000 Trial Comparing ABVD Versus BEACOPP Versus Copp/EBV/CAD in Patients with Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma
ASH 2014: Highlights in Hodgkin Lymphoma published on December 16, 2014
Craig Moskowitz, MD discusses the Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression
ASH 2014: Highlights in Hodgkin Lymphoma published on December 16, 2014
Julie Vose, MD discusses abstract #293 Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

Results 1 - 3 of 3

Managing HL would like to recognize and thank Merck & Co., Inc., Seattle Genetics, and Takeda Oncology for their educational support of ManagingHodgkinLymphoma.com

©2017 MediCom Worldwide, Inc. All rights reserved